23:02 , Jul 10, 2019 |  BC Extra  |  Company News

Yumanity’s Coles picks Merrimack, Onyx alum Peters to lead company to the clinic

As it gears up to enter the clinic next quarter, neurodegeneration company Yumanity hired Richard Peters as CEO to succeed Tony Coles, aiming to leverage Peters’ experience managing neurology trials into at least three clinical...
09:01 , Jun 19, 2019 |  BC Extra  |  Financial News

Coenzyme A company Comet debuts with $28.5M series A

Led by former Syntimmune CEO David de Graaf, Comet launched Wednesday with $28.5 million in series A funding to develop precursors of coenzyme A to treat metabolic, immune and neurological disorders that involve dysregulated coenzyme...
00:02 , Jun 19, 2019 |  BC Extra  |  Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

CTTQ, Akeso form JV to develop PD-1 mAb  The Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd. (HKEX:1177) formed a 50/50 joint venture with Akeso Biopharma Inc. (Zhongshan, China) to...
22:10 , May 20, 2019 |  BC Extra  |  Politics & Policy

Community Oncology Alliance pushing alternative to pricing index for Part B drugs

The Community Oncology Alliance is in discussions with congressional staff and the Trump administration about modifying the existing Medicare Part B payment structure as an alternative to the International Pricing Index that HHS Secretary Alex...
19:48 , May 14, 2019 |  BC Innovations  |  Distillery Therapeutics

Two generic antifungals and cerivastatin for biliary, pancreatic cancers

DISEASE CATEGORY: Cancer INDICATION: Biliary cancer; pancreatic cancer Organoid studies suggest that amoralfine, fenticonazole or cerivastatin could help treat intrahepatic cholangiocarcinoma (IHCC), gallbladder cancer, neuroendocrine carcinoma (NEC) of the ampulla of Vater, and pancreatic ductal...
19:52 , Mar 29, 2019 |  BC Extra  |  Preclinical News

NCI team details method to improve T cell therapies

A team led by NCI's Nicholas Restifo showed raising potassium levels or adding a citrate derivative when manufacturing adoptive T cell therapies could improve antitumor efficacy. Reported in a Science paper , the researchers showed...
23:21 , Mar 7, 2019 |  BC Extra  |  Company News

Moderna announces pipeline updates in first financial results

In its first quarterly financial results as a public company, Moderna announced its first rare disease mRNA program is heading to the clinic. Moderna Inc. (NASDAQ:MRNA) said Wednesday that it has submitted an IND for...
13:48 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer Cell culture and mouse studies suggest inhibiting the HMG-CoA reductase/SQLE/LSS pathway could help treat p53-deficient liver cancer. In human liver adenocarcinoma cell lines, levels of two metabolic intermediates biosynthesized by the pathway...
21:59 , Dec 6, 2018 |  BC Week In Review  |  Clinical News

Yumanity reveals Parkinson's candidate as first compound from yeast platform

Yumanity Therapeutics LLC (Cambridge, Mass.) and colleagues used the company's yeast platform to identify inhibitors of the enzyme stearoyl-CoA desaturase-1 (SCD1) that could prevent α-synuclein toxicity in Parkinson's disease. The SCD1 inhibitors are the first...
23:59 , Dec 4, 2018 |  BC Extra  |  Preclinical News

Yumanity reveals Parkinson's candidate as first compound from yeast platform

Yumanity Therapeutics LLC (Cambridge, Mass.) and colleagues used the company's yeast platform to identify inhibitors of the enzyme stearoyl-CoA desaturase-1 (SCD1) that could prevent α-synuclein toxicity in Parkinson's disease. The SCD1 inhibitors are the first...